Open Access Medical Books



Edited by Iván Díaz-Padilla .

382 pages . 

Ovarian cancer can no longer be considered one disease entity, but a heterogeneous group of diseases. Our understanding of its clinical and molecular complexity is improving notably over the last decade. This is of utmost importance when it comes to determine the most adequate treatment strategy for each individual patient. Despite not being the most frequent tumor, ovarian cancer has the highest mortality rate amongst gynecological cancers. The absence of specific symptoms and the lack of a universally and validated screening strategy leads to a delayed diagnosis, when the tumor has spread beyond the ovaries. Despite most patients are diagnosed at advanced stages, aggressive cytoreductive surgery and combination chemotherapy is recommended. This therapeutic approach may control the disease for some time, but a great majority of patients experience relapses within the first two years of primary treatment. Relapsed ovarian cancer is no longer a curable disease and chemotherapy is the mainstay of treatment in that scenario. Ovarian cancer has been traditionally considered a chemosensitive tumor. However, the development of resistance to cytotoxics is a major problem. New molecularly targeted agents are actively being investigated in an attempt to improve the outcome of this patient population.
Stemmed from the complexity of ovarian cancer, high-scale medical specialization is therefore needed. Ideally, ovarian cancer patients should be treated in tertiary institutions, where higher volumes of complex cytoreductive procedures are performed. It is likely that a strong link with a clinical research facility may also derive in benefit for patients, having immediate access to the latest treatment opportunities within clinical trials. Considerable efforts are also underway in early diagnosis and identification of new biomarkers that may help in predicting response to treatment.
The present book encompasses most of the key aspects pertaining the current of diagnosis and treatment of ovarian cancer. It is intended to cover topics from clinical epidemiology to the latest advances in biomarker development and new drugs. The present publication has counted with the valuable contribution of renowned international experts in the field of ovarian cancer, to whom I want to express my most sincere gratitude. We hope that our target readership (general gynecologists, medical oncologists, gynecologic oncologists) will
find this book as a useful and valuable reference in their daily practice.

Ivan Diaz-Padilla, M.D.
Consultant Medical Oncologist
Head, Gynecologic Cancer Program
Centro Integral Oncologico Clara Campal
Hospital Universitario HM Sanchinarro


Section 1 of the textbook : Clinical Epidemiology of Ovarian Cancer ,

1 In what Setting Should Women with Ovarian Cancer Receive Care? 3 Laurie Elit and Clare Reade

2 Quality of Life in Ovarian Cancer Treatment and Survivorship 27 Vânia Gonçalves

3 Preventive Strategies for Ovarian Cancer 45 L. Cortesi, A. Toss and E. De Matteis

Section 2 of the textbook : Pathology ,

4 Borderline Epithelial Tumors of the Ovary 77 Gennaro Cormio, Vera Loizzi, Maddalena Falagario, Doriana Scardigno, Luigi E. Selvaggi and Donatella Latorre

5 Implication of Clear Cell and Mucinous Histology 97 Jun Naniwa, Hiroaki Itamochi and Junzo Kigawa

6 Demographic and Clinical Characteristics of Mucinous Epithelial Ovarian Cancer, and Survival Following a Mucinous Epithelial Ovarian Cancer Diagnosis 117 Sherri L. Stewart, Jennifer M. Wike, Trevor D. Thompson, Rosemary D. Cress, Amy R. Kahn, Cynthia D. O’Malley and Maria J. Schymura

7 The Genetics of Ovarian Cancer 135 Constantine Gennatas

Section 3 of the textbook : Ovarian Cancer Therapeutics .

8 Surgical Treatment of Ovarian Cancer 161 Lucas Minig, M. Guadalupe Patrono, Rafael Alvarez Gallego, Javier Valero de Bernabé and Ivan Diaz-Padilla

9 The Role of Chemotherapy in Recurrent Ovarian Cancer 183 Miguel Angel Alonso Bermejo, Ana Fernandez Montes, Eva Perez Lopez, Miguel Angel Nuñez Viejo, Jesus Garcia Gomez and Jesus Garcia Mata

10 Molecular Mechanisms of Platinum Resistance in Ovarian Cancer 205 Gonzalo Tapia and Ivan Diaz-Padilla

Section 4 of the textbook : Molecular Pathogenesis and Targeted Therapies .

11 Biological Significance of Apoptosis in Ovarian Cancer: TRAIL Therapeutic Targeting 227
Nadzeya Goncharenko-Khaider, Denis Lane, Isabelle Matte, Claudine Rancourt and Alain Piché

12 Protein Kinase G-Iα Hyperactivation and VASP Phosphorylation in Promoting Ovarian Cancer Cell Migration and Platinum Resistance 251 Janica C. Wong and Ronald R. Fiscus

13 The PI3K/Akt/mTOR Pathway in Ovarian Cancer: Biological Rationale and Therapeutic Opportunities 275 Alexandra Leary, Edouard Auclin, Patricia Pautier and Catherine Lhommé

14 PARP Inhibitors in Ovarian Cancer 303 Jeanine Staples and Annekathryn Goodman

Section 5 of the textbook : Biomarkers .

15 The Merit of Alternative Messenger RNA Splicing as a New Mine for the Next Generation Ovarian Cancer Biomarkers 327 Jean-Philippe Brosseau and Sherif Abou-Elela

16 Ovarian Cancer in vitro Diagnostics: New Approaches to Earlier Detection 349 Jorge Tapia, Mercedes de Alvarado, Benjamín Bustos, Vania Lukoviek and Gregory E. Rice

17 Disseminated Tumor Cells and Cancer Stem Cells in Ovarian Cancer 359 Malgorzata Banys, Natalia Krawczyk, Andreas D. Hartkopf and Tanja Fehm .

You've just read an article category Obstetrics and Gynecology / Oncology and Hematology by title TEXTBOOK : OVARIAN CANCER - A CLINICAL AND TRANSLATIONAL UPDATE. You can bookmark this page URL Thank you!
Published by: Unknown - Thursday, February 28, 2013


Post a Comment